Beta-Blocker Evaluation in Survival Trial (BEST)

Note that you will be prompted to log in or register an account

Accession Number

Study Type
Clinical Trial

Collection Type
Open BioLINCC Study See bottom of this webpage for request information

Study Period

NHLBI Division

Dataset(s) Last Updated
January 3, 2018


Commercial Use Data Restrictions No

Data Restrictions Based On Area Of Research No


The Beta-Blocker Evaluation of Survival Trial was designed to determine whether bucindolol hydrochloride- a nonselective beta-adrenergic blocker and mild vasodilator- would reduce the rate of death from any cause among patients with advanced heart failure and to assess its effects in various subgroups defined by ethnic background and demographic criteria- specifically women and members of minority groups.


Although beta-adrenergic-receptor antagonists reduce morbidity and Mortality in patients with mild-to-moderate chronic heart failure, their effort on survival in patients with more advanced heart failure is unknown.


A total of 2,708 patients with heat failure and a left ventricular ejection fraction of 35 percent or lower were randomly assigned to double-blind treatment with either bucindolol (1,354 patients) or placebo (1,354 patients) and followed for the primary end point of death from any cause.


Bucindolol resulted in no significant overall survival benefit. (N Engl J Med 2001;344:1659-67)

Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in. If you are not registered on this site, you can do so via the Request button. Registration is quick, easy and free.

Resources Available

Study Datasets Only

Study Documents

Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.